Abstract: FR-PO1130
SGLT2 Inhibitors and Long-Term Risk of CKD in Kidney Donors with Type 2 Diabetes and Obesity: Global Cohort Study Using Real-World Data
Session Information
- Transplantation: Clinical - Transplant Access, Recipient Evaluation, Living Donors, Pregnancy, and More
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2002 Transplantation: Clinical
Authors
- Kaur, Gurwant, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Tahir, Maria, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Raza, Muhammad, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Siddiqi, Mahwash, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Ghahramani, Nasrollah, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Group or Team Name
- Penn State Nephrology
Background
Diabetes Mellitus type 2 (DM) and obesity are known risk factors for chronic kidney disease (CKD). We aimed to assess the incidence of CKD IV-V among patients with KD, DM, obesity class 1, and CKD III with and without the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i).
Methods
Using the TriNetX Research Network, cohort 1 (n = 51, 21 HCO) identified patients with KD, DM, obesity class 1, and CKD III with use of sodium-glucose co-transporter 2 inhibitors (SGLT2i). Cohort 2 (n = 136, 30 HCO) identified patients with KD, DM, obesity class 1, and CKD III without the use of SGLT2i. Outcomes were evaluated from one day post-index event through the available follow-up period. The primary outcome was risk of CKD III-V. Kaplan-Meier survival curves, survival probability (SP), hazard ratios (HR), and risk ratios (RR) were calculated.
Results
Patients with KD, DM, obesity class 1, and CKD III with SGLT2i (cohort 1) had significantly increased risk of CKD IV: 35.29% vs. 19.1% (RR 1.84; SP 41.69% vs. 61.52%; HR 2.47) compared to the control group (cohort 3). Sample size was too small to calculate the risk of CKD V among the cohorts (2 & 3).
Conclusion
In this large, multicenter real-world cohort, the use of SGLT2i was strongly associated with increased risk of CKD IV among KD with DM, obesity class 1, and CKD III. These findings underscore the need for long-term nephrology follow-up and assess the risk of CKD progression for such patients.